Best Performing Stocks To Invest In Right Now

In November, everyone was talking about Jean-Claude Van Damme’s Volvo Truck demonstration where he did an “epic” split between two moving trucks.

The fascinating scene went viral on YouTube with more than 68 million views, Van Damme saw a career resurgence and Volvo Truck sales rose 31 percent in November, according to the Wall Street Journal.

Now promoting his film, Welcome to the Jungle (in theaters and VOD February 7), Van Damme tells USA TODAY over email that performing the stunt was a concern for the action star.

“In action films that involve stunts there is always a risk,” says Van Damme. “I would be less than candid if I didn’t admit that I was concerned from time to time, when you are not concerned, you get careless, and then you get hurt.”

However, when he shot the tranquil-looking scene, he insists that the only thing going through his mind was “the music of Enya.” The Irish singer also sings in the finished product.

Best Performing Stocks To Invest In Right Now: U.S. Physical Therapy Inc.(USPH)

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical and occupational therapy clinics in the United States. Its clinics provide pre-and-post operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company also offers physician services to third parties; and operates clinics, which specialize in the outpatient, non-surgical treatment of osteo arthritis degenerative joint disease and other musculoskeletal conditions. As of December 31, 2011, it operated 416 clinics in 42 states; and managed 15 physical therapy facilities for third parties, including physicians. The company focuses its marketing efforts on physicians comprising orthopedic surgeons, neurosurgeons, physiatrists, internal medicine physicians, podiatrists, occupational medicine physicians, and general practitioners. U.S. Physical Therapy, Inc. was founded in 1 990 and is based in Houston, Texas.

Advisors’ Opinion:

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on US Physical Therapy (NYSE: USPH  ) , whose recent revenue and earnings are plotted below.

Best Performing Stocks To Invest In Right Now: The Ultimate Software Group Inc.(ULTI)

The Ultimate Software Group, Inc., together with its subsidiaries, designs, develops, and markets unified human capital management software-as-a-service solutions to businesses in the United States and Canada. Its UltiPro software solution offers businesses with cloud-based functionality to manage the employment life cycle from recruitment to retirement. The UltiPro solution includes feature sets for talent acquisition and onboarding, human resource management and compliance, benefits management and online enrollment, payroll, performance management, salary planning and budgeting for compensation management, succession management, reporting and analytical decision-making tools, and time and attendance, as well as role-based access for executives, managers, administrators, and employees. The company offers its products and services for various industries, including manufacturing, food services, sports, technology, finance, insurance, retail, real estate, transportation, com munications, healthcare, and other services. It also provides implementation, training, maintenance, and technical support services. The Ultimate Software Group, Inc. markets its products under the UltiPro Enterprise and UltiPro Workplace brand names through its direct sales teams. The company was founded in 1990 and is headquartered in Weston, Florida.

Advisors’ Opinion:

  • [By Jeremy Bowman]

    What: Shares of Ultimate Software (NASDAQ: ULTI  ) were screaming “Ultimate!” today, gaining as much as 17% after topping estimates in its quarterly report.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Ultimate Software Group (Nasdaq: ULTI  ) , whose recent revenue and earnings are plotted below.

Best Performing Stocks To Invest In Right Now: Microsemi Corporation(MSCC)

Microsemi Corporation engages in the design, manufacture, and marketing of analog and mixed-signal integrated circuits (IC) and semiconductors primarily in the United States, Europe, and Asia. Its products include individual components and IC solutions that offer light, sound, and power management for desktop and mobile computing platforms, LCD TVs, and other power control applications. These products are used in notebook computers, data storage, wireless local area network, LCD backlighting, LCD TVs, LCD monitors, automobiles, telecommunications, test instruments, defense and aerospace equipment, sound reproduction, and data transfer equipment. The company?s semiconductor products include silicon rectifiers, zener diodes, low leakage and high voltage diodes, temperature compensated zener diodes, transistors, subminiature high power transient suppressor diodes, and pin diodes used in magnetic resonance imaging (MRI) machines. It also manufactures semiconductors for commer cial applications, such as automatic surge protectors, transient suppressor diodes used for telephone applications, and switching diodes used in computer systems. In addition, the company provides electronic components and systems for the defense and aerospace markets; multi-band radio frequency integrated circuit solutions; and anti-tamper solutions to defense clients in securing systems against tampering, piracy, and reverse engineering. It markets its products directly, as well as through electronic component distributors and independent sales representatives to the defense and security, aerospace, enterprise and communication, and industrial and alternative energy markets. The company was formerly known as Microsemiconductor Corporation and changed its name to Microsemi Corporation in February 1983. Microsemi Corporation was founded in 1960 and is headquartered in Aliso Viejo, California.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Equities Trading DOWN
    Shares of Microsemi (NASDAQ: MSCC) were down 4.18 percent to $23.16 after the company issued a downbeat Q1 outlook.

  • [By Lauren Pollock]

    Microsemi Corp.(MSCC) agreed to pay almost $298 million to acquire Symmetricom Inc.(SYMM), a deal that will expand the power-management supplier’s exposure into the aerospace and defense industries while also immediately adding to earnings. Shares in Symmetricom soared.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Microsemi (Nasdaq: MSCC  ) , whose recent revenue and earnings are plotted below.

Best Performing Stocks To Invest In Right Now: Franklin Resources Inc.(BEN)

Franklin Resources Inc. is a publicly owned asset management holding company. The firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It manages, through its subsidiary, separate client-focused equity, fixed income, and balanced portfolios. The firm also launches equity, fixed income, and balanced mutual funds. It launches hedge funds and provides retirement plans to its clients through its subsidiaries. The firm invests in the public equity and fixed income markets across the globe through its subsidiaries. Franklin Resources, Inc was founded in 1947 and is based in San Mateo, California with additional offices in Edinburgh, United Kingdom, Fort Lauderdale, Florida, St. Petersburg, Florida, Hong Kong, China, Melbourne, Australia, Sydney, Australia, Nassau, Bahamas, New York City, Paris, France, Rancho Cordova, California, and Toronto, Ontario.

Advisors’ Opinion:

  • [By Dan Caplinger]

    In the following video, Dan Caplinger, The Motley Fool’s director of investment planning, goes through a few situations where an IRA rollover might not be ideal. Dan notes that Franklin Templeton (NYSE: BEN  ) , AllianceBernstein (NYSE: AB  ) , Goldman Sachs (NYSE: GS  ) , and other companies often offer cheaper class of mutual funds that would otherwise carry sales loads or higher fees outside a 401(k). Dan also talks about company stock and the special rules for 401(k)s that own it, as well as the importance of looking at overall fees to decide if your 401(k) is the best place to invest or whether an IRA rollover will help you more.

  • [By Tim Melvin]

    The flood of 13F filings has begun in advance of this week’s deadline. Among the early filers is Michael Price, the once well-known and widely followed value investor. Price compiled an incredible track record at the Mutual Series Funds before selling the operation to Franklin Templeton (BEN) and then retiring a few years later.

Best Performing Stocks To Invest In Right Now: Zogenix Inc (ZGNX)

Zogenix, Inc. (Zogenix), incorporated on May 11, 2006, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company’s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Sumavel DosePro may serve as a treatment alternative to oral and nasal triptans and offers administration when compared to traditional, needle-based sumatriptan injection. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).

The Company’s collaboration with Astellas has been terminated on March 31, 2012. Sumavel DosePro is a pre-filled, single-use disposable, needle-free drug delivery system that subcutaneously delivers 6 mg of sumatriptan in 0.5 mL of sterile liquid. Sumavel DosePro is designed to be portable, intuitive and easy-to-use. To use, the patient simply snaps off a plastic tip, flips back a lever and presses the end of the delivery system to the skin of the abdomen or thigh. Under the force of a small amount of compressed nitrogen gas, the liquid form of sumatriptan is expelled out of the device as a thin jet of medication, which pierces the skin and selectively deposits into the subcutaneous tissue.

Zogenix competes with GlaxoSmithKline, AstraZeneca PLC, Endo Pha rmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., ! Inc., Pfizer Inc., Alexza Pharmaceuticals, Inc., MAP Pharmaceuticals, Inc., Abbott Laboratories, Alpharma Inc., Endo Pharmaceuticals Holdings Inc., King Pharmaceuticals, Inc., Mallinckrodt Inc., Purdue Pharma L.P., Teva Pharmaceutical Industries Limited, Watson Pharmaceuticals, Inc., Becton, Dickinson and Company, Owen Mumford Ltd., Ypsomed, Sandoz Inc., Bioject Inc. and Antares Pharma Inc.

Advisors’ Opinion:

  • [By Lauren Pollock]

    The Food and Drug Administration approved an extended-release version of the narcotic painkiller hydrocodone despite a recommendation by its advisory committee that the drug should be rejected because of its potential for abuse. The federal agency approved Zohydro ER from Zogenix Inc.(ZGNX), the first hydrocodone product not mixed with milder painkillers such as acetaminophen and also the first extended-release hydrocodone product. Shares rose 15% to $3.49 premarket.

  • [By Monica Gerson]

    Zogenix (NASDAQ: ZGNX) shares gained 9.21% to $3.32 in the pre-market session after the company won the FDA approval for Zohydro ER capsules.

    Ariad Pharmaceuticals (NASDAQ: ARIA) soared 5.06% to $3.74 in the pre-market trading. ARIAD Pharmaceuticals is expected to report its Q3 financial results on November 6, 2013.

Best Performing Stocks To Invest In Right Now: Advantest Corp (ATE)

Advantest Corporation, incorporated in December 1954, is a part of Advantest group. The Company operates in three segments: semiconductor and component test system segment; mechatronics system segment, focusing on peripheral devices including test handlers and device interfaces, and services, support and others segment. The semiconductor and component test system segment provides customers with test system products for the semiconductor industry and the electronic component industry. The mechatronics system segment focuses on peripheral devices to the semiconductor and component test systems. The services, support and others segment consists of comprehensive customer solutions provided in connection with the semiconductor and component test system and mechatronics system segments, support services and an equipment lease business.

Semiconductor and Component Test Systems Segment

Semiconductor and component test systems are used during the semicond uctor and electronic component manufacturing process to confirm that a semiconductor functions properly. Semiconductor and component test systems consist of test systems for memory semiconductors and test systems for non memory semiconductors. Advantest’s test systems for memory semiconductors are test systems designed to test high-speed/high performance dynamic random access memory (DRAM) semiconductors used in equipment such as personal computers and servers, as well as flash memory semiconductors used in digital consumer products.

Test systems for memory semiconductors consist of a mainframe and one or more test heads. During testing, a device interface is attached to the test head. During the front-end testing process, wafers are loaded by a prober and are connected to the test system for memory semiconductors through the device interface. Electric signals between the die and the test systems for memory semiconductors are transmitted through probe pins lo cated in the device interface and tested. After front-end te! sting is completed, the wafer is diced into separate dies and properly functioning dies are packaged. During back-end testing, test handlers are used to load these packaged devices onto the test heads, and electric signals are transmitted between the devices and the test heads via the device interface and tested. The test results are analyzed by the test systems for memory semiconductors’ hardware circuits and software programs. Customized software programs for each semiconductor are required to analyze the semiconductor tests and test data.

Advantest’s main product lines of test systems for memory semiconductors are the T5500 series, the T5300 series and the T5700 series. The T5593 is a test system targeted at the market for high speed memory semiconductors, such as DDR2- Synchronous Dynamic Random Access Memory (SDRAM) and Synchronous Graphics Random Access Memory (SGRAM). The T5383 is a multi-functional test system for memory semiconductors that reduces testing costs for semiconductor manufacturers. Advantest’s main line of test systems for non memory semiconductors relates to test systems for SoC semiconductors, test systems for liquid crystal display (LCD) driver integrated circuits and test systems for semiconductors used in car electronics. The T6577 test systems for SoC semiconductors in the T6500 series were primarily developed to test micro controller unit (MCU) and SoC semiconductors that control digital consumer products at the production lines. The T6300 series are test systems for LCD driver integrated circuits used with high-definition LCD displays. The T7721, T7722 and T7723 are test systems for non memory semiconductors for mixed signal integrated circuits. The T8571A is a test system for non memory semiconductors that is primarily used to evaluate and analyze CCDs which are image sensors.

Mechatronics System Segment

The Main products in the Mechatronics System Segment are test han dlers which handle semiconductor devices and automate the te! sting, an! d device interfaces which are the interfaces with devices being tested. Test handlers are used with semiconductor and component test systems to handle, condition temperature, contact and sort semiconductors and other electronic components during the back-end testing of the semiconductor manufacturing process. Advantest’s test handlers are sold primarily in conjunction with the sale of its semiconductor and component test systems. The M6242 test handler for test systems for memory semiconductors, including DDR-3SDRAM, can handle up to 512 semiconductors at a time. Advantest’s test handlers for non memory semiconductors, including SoC semiconductors, are the M4841, the M4741A and the M4742A, among others.

Advantest develops and manufactures device interfaces for semiconductor and component test systems and supplies device interfaces, such as high performance and high density connectors, socket boards and sockets. For test systems for memory semiconductors, Ad vantest provides motherboards capable of handling a maximum of 512 semiconductors at a time. For test systems for non memory semiconductors, Advantest provides motherboards that are compatible with a maximum of 3,072 signals. Advantest also provides motherboards designed for use in front-end testing. Advantest provides custom manufacturing of socket boards and performance boards for each device under test in accordance with customers’ specifications.

Advantest provides sockets for test systems for memory semiconductors. Advantest provides low-inductance (0.4nH) sockets and fine pitch (0.4mm) sockets for semiconductors that are becoming more high-speed and more compact in size. Advantest provides carrying and contacting mechanism components compatible with each device under test for test handlers for memory semiconductors and test handlers for non memory semiconductors.

Services, Support and Others Segment

In the services, support a nd others segment, Advantest has focused on maintenance serv! ices, suc! h as installation and repair of Advantest’s products. It also focused on lease and rental services of its products as a part of Advantest’s effort to provide customers with comprehensive solutions.

The Company competes with Teradyne, Inc., Verigy Ltd., LTX-Credence Corporation, Yokogawa Electronic Corporation, FROM30 CO., LTD., EXICON Ltd., UniTest Inc., Delta Design, Inc., Seiko Epson Corporation, Mirae Corporation, TechWing, Inc., TSE Co., Ltd. and Secron Co., Ltd.

Advisors’ Opinion:

  • [By Dan Carroll]

    Nissan’s done better this year than electronics maker Advantest (NYSE: ATE  ) , but this stock absolutely blew up over the past week. Advantest’s shares shot higher by more than 9%, wiping out pessimism over the company’s weak earnings released a few weeks ago. Advantest’s net loss and operating profit both fell below its guidance, and despite this week’s investor optimism, the future’s murky for this company. Financial site TheStreet downgraded the stock last week, citing Advantest’s falling earnings, among other issues.

Best Performing Stocks To Invest In Right Now: Penn National Gaming Inc.(PENN)

Penn National Gaming, Inc. and its subsidiaries own and manage gaming and pari-mutuel properties in the United States. It operates approximately 27,000 gaming machines; 500 table games; and 2,000 hotel rooms in 23 facilities in 16 jurisdictions, including Colorado, Florida, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland, Mississippi, Missouri, New Jersey, New Mexico, Ohio, Pennsylvania, West Virginia, and Ontario. The company was formerly known as PNRC Corp. and changed its name to Penn National Gaming, Inc. in 1994. Penn National Gaming, Inc. was founded in 1982 and is based in Wyomissing, Pennsylvania.

Advisors’ Opinion:

  • [By Patricio Kehoe] the measures taken to balance out revenue in case of headwinds.

    Valuation and Contracts

    One factor that plays in this firm’s favor is NASCAR’s long-term contracts with major TV networks and radio stations. The most recent deal is set to launch in 2015, and will bind the motorsport brand for 10 years to NBC and Twenty-First Century Fox Inc. (FOX), for a total of $8.2 billion (45% annual increase over the current contract). Although a more stable economic scenario may reignite concessionary spending among customers, and cause the motorsport segment to gain popularity again, the non-existent switching costs and alternative leisure choices could be detrimental to this company. Also, ISCA’s current $87.9 million cash flow will likely be stagnated by the new Daytona Ring Project, which is expected to cost $400 million over the next five years.

    Furthermore, concerns remain regarding the company’s growth metrics, especially given their downward trend. For the fourth quarter in 2013, revenue showed negative growth of 0.5%, a downfall which ISCA has not been able to stall since 2007. Operating margins have also fallen by 9% in the past two years (currently at 12.8%), in addition to the below average (2.02%) dividend yield of 0.70%. Added to a premium P/E value of 33.00x trailing earnings, compared to the industry average of 22.40x, I feel bearish about this motorsports giant’s near-term profitability and see some uncertainty in the long-term future.

    Disclosure: Patricio Kehoe holds no position in any stocks mentioned.

    About the author:Patricio KehoeA fundamental analyst at Lone Tree Analytics

  • [By Lisa Levin]

    Penn National Gaming (NASDAQ: PENN) shares fell 1.71% to reach a new 52-week low of $12.05. Penn National Gaming is expected to report its Q4 results on February 6.

  • [By Paul Ausick]

    Stocks on the Move: BlackBerry Ltd. (NASDAQ: BBRY) is down 16.4% at $6.50 after announcing that no buyout bid will be forthcoming. Penn National Gaming Inc. (NASDAQ: PENN) is down 76.7% at $13.75 after spinning-off its real-estate holdings into a REIT. Suntech Power Holdings Co. Ltd. (NYSE: STP) is up 15.5% at $1.53 following the acquisition of its major operations in Wuxi.

Best Performing Stocks To Invest In Right Now: IGI Laboratories Inc. (IG)

IGI Laboratories, Inc. engages in developing, manufacturing, filling, and packaging topical semi-solid and liquid products for cosmetic, cosmeceutical, and pharmaceutical customers in the United States. The company’s products are used for various skin conditions, including the treatment of symptoms of dermatitis, acne, psoriasis, and eczema. It offers contract formulation and contract manufacturing services to a range of topical formulations, including creams, ointments, lotions, gels, and topical liquids. The company is also developing a portfolio of prescription generic formulations in topical dosage forms. IGI Laboratories, Inc., through its license agreement with Novavax, Inc., utilizes the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological over-the-counter and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008. IGI Laboratories, Inc. was founded in 1977 and is based in Buena, New Jersey.

Advisors’ Opinion:

  • [By Holly LaFon]

    The Barclays Aggregate Index rose by 0.57% in 3Q13, having stood at a loss of -0.36% the day before the FOMC’s declaration to not slow QE. Despite the bounce, the Index remains in negative territory YTD and for the trailing 12-months at -1.77% and -1.68%, respectively. In stark contrast to 2Q13, Investment Grade (IG) corporate spreads tightened 10bps during 3Q13, producing a positive nominal return of 0.82% and an excess return of 0.92%. The respective YTD total returns in IG remain a disappointing -2.62%, but excess returns are still positive at 0.61% YTD. The 1-Yr results for IG Credit now fall to a nominal -1.58%, but 1.79% in excess of Treasuries.

Best Performing Stocks To Invest In Right Now: VIVUS Inc (VVUS)

VIVUS, Inc., incorporated on May 16, 1996, is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The Company’s drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug al so includes STENDRA, or avanafil.

Qsymia for the treatment of obesity was approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate.

The Company initially launched Qsymia for distribution to eligible patients through the home delivery networks of two certified pharmacies, CVS Pharmacy and Walgreens. Since then, it has expanded the distribution of Qsymia to include the home delivery networks of Express Scripts, Wal-Mart Pharmacy and, for its members only, Kaiser Permanente. Clinical studies of topiramate, a component of Qsymia, in type 2 diabetics resul ted in a clinically reduction of hemoglobin A1c (HbA1c). The! Company’s drug, STENDRA (avanafil), is an oral PDE5 inhibitor the Company has licensed from Mitsubishi Tanabe Pharma Corporation (MTPC).

Advisors’ Opinion:

  • [By James Brumley]

    Think Arena Pharmaceuticals (ARNA) and VIVUS (VVUS) used up all weight loss drug enthusiasm when the two companies won approval for Belviq and Qsymia, respectively, back in 2012?

  • [By Roberto Pedone]

    Another under-$10 biopharmaceutical player that look ready to trigger a tradable breakout is Vivus (VVUS), which is engaged in the development and commercialization of therapeutic products for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men’s sexual health. This stock has been hammered by the bears so far in 2013, with shares off by 26%.

    If you take a look at the chart for Vivus you’ll notice that this stock recently formed a double bottom chart pattern at $9.30 to $9.33 a share. Shares of VVUS have now started to spike higher of $9.33 a share and back above its 50-day moving average of $9.73 a share. That move is quickly pushing shares of VVUS within range of triggering a near-term breakout trade.

    Market players should now look for long-biased trades in VVUS if it manages to break out above some near-term overhead resistance at $10.29 a share high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 2.35 million shares. If that breakout hits soon, then VVUS will set up to re-test or possibly take out its next major overhead resistance levels at $11.44 to $11.64 a share, or its 200-day moving average at $11.76 a share. Any high-volume move above those levels will then give VVUS a chance to tag its next major overhead resistance level at $13 a share.

    Traders can look to buy VVUS off weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support levels at $9.33 to $9.30 a share, or just blow $9 a share. One can also buy VVUS off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By Bryan Murphy]

    If you’re curious as to why shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) are tanking following what was seemingly good news, you only have to look at the sagas of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and VIVUS, Inc. (NASDAQ:VVUS) to find your answer. Both ARNA and VVUS shares fell – precipitously – after each of those companies came up with similar (though better, technically) news. The downside for OREX shares is, not only are they apt to struggle for the same dynamic/technical reason VIVUS and Arena shares did, but the market has had a chance to see a major fundamental reason that Orexigen could be in trouble.

  • [By John Udovich]

    On Tuesday, small cap EnteroMedics Inc (NASDAQ: ETRM) soared 63.5% after reporting new clinical trial data for its Maestro system that is designed to control obesity, meaning it might be time to take a closer look at the stock along with the performance of other small cap obesity drug or treatment players like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS).

Best Performing Stocks To Invest In Right Now: NxStage Medical Inc.(NXTM)

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product, the NxStage System One, is a portable hemodialysis system used for home hemodialysis and a range of dialysis therapies for chronic home hemodialysis treatment, and the treatment of acute kidney failure and fluid overload. The NxStage System One comprises components, such as The NxStage Cycler, a compact portable electromechanical device; The NxStage Cartridge, a single-use integrated treatment cartridge; and premixed dialysate for hemodialysis applications. The company also sells a line of extracorporeal disposable products for use primarily for in-center dialysis treatments for patients with end-stage renal disease (ESRD); and needles and blood tubing sets primarily to dialysis clinics for the treatment of ESRD. NxStage Medical, Inc. markets its products primaril y to dialysis clinics, nephrologists, and hospitals through distributors and sales representatives in the United States, Mexico, and Europe. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. founded in 1998 and is headquartered in Lawrence, Massachusetts.

Advisors’ Opinion:

  • [By John Udovich]

    Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA) and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM).